Dietary capsanthin, the main carotenoid in paprika (*Capsicum annuum*), alters plasma high-density lipoprotein-cholesterol levels and hepatic gene expression in rats

Koichi Aizawa* and Takahiro Inakuma

Corporate Planning Division, Research Institute, Kagome Co., Ltd, 17 Nishitomiyama, Nasushiobara-shi, Tochigi 329-2762, Japan

(Received 9 January 2009 – Revised 22 June 2009 – Accepted 23 June 2009 – First published online 31 July 2009)

The effects of dietary capsanthin, the main carotenoid in paprika (*Capsicum annuum*), on lipid metabolism were examined. Young male Wistar rats were fed diets containing paprika powder, paprika organic solvent extract, residue of paprika extract, and purified capsanthin. Administration of purified capsanthin for 2 weeks resulted in a significant increase in plasma HDL-cholesterol (P<0.05) without detectable differences in plasma total cholesterol and TAG concentrations. A statistically significant correlation (r 0.567; P<0.001) was found between dietary capsanthin concentrations and plasma HDL-cholesterol concentrations. Animals receiving diets containing two different capsanthin concentrations exhibited dose-dependent increases in plasma HDL-cholesterol (r 0.597; P<0.005). While capsanthin was absent in the liver of animals fed the basal diet, it increased markedly in capsanthin-fed animals (P<0.001). Quantitative analyses of hepatic mRNA levels revealed that capsanthin administration resulted in up-regulation of mRNA for apoA5 and lecithin cholesterol acyltransferase (LCAT), without significant differences in other mRNA levels related to HDL-cholesterol metabolism. These results suggest that capsanthin had an HDL-cholesterol-raising effect on plasma, and the potential to increase cholesterol efflux to HDL particles by increasing apoA5 levels and/or enhancement of LCAT activity.

**Paprika: Capsanthin: Lipid metabolism: Hepatic genes**

CVD is one of the leading causes of morbidity and mortality worldwide. It is suggested that low levels of HDL-cholesterol constitute an independent risk factor for CVD(1–3). Also, a recently concluded clinical intervention trial supports the idea that increasing the levels of HDL-cholesterol can protect against clinical CVD(4). Based on these observations and current concepts regarding the antiatherogenic roles of HDL in promoting reverse cholesterol transport(5) and as an antioxidant (6), interventions involving the atherogenic roles of HDL in promoting reverse cholesterol transport(5) and as an antioxidant (6), interventions involving

Ripe paprika fruit (*Capsicum annuum*) is widely used as a vegetable and food additive, as this fruit is considered to be a good source of carotenoid pigments. Capsanthin is the major carotenoid present in paprika, and is present in an acylated form with fatty acids(11,12). This carotenoid, which does not possess provitamin A activity, has been shown to be effective as a free-radical scavenger(13).

Oshima et al.(14) studied the accumulation and clearance of capsanthin in the plasma of human males after ingestion of paprika juice. These studies revealed that dietary capsanthin was absorbed into the body and distributed to plasma lipoproteins. Furthermore, it was confirmed that xanthophylls, including capsanthin, are distributed to HDL in larger amounts than to LDL, when compared with hydrocarbon carotenoids. Xanthophylls can act as antioxidants against free radical attack and exposure to singlet oxygen in plasma lipoproteins(15,16).

Therefore, dietary xanthophylls seem to participate in the primary defence mechanism of HDL against oxidative stress, and may also be expected to affect lipid metabolism and/or maintain favourable blood lipid profiles. In fact, some reports have suggested that certain carotenoids may affect HDL-cholesterol concentrations(17,18) and alter adipocytokine levels(19,20) or hepatic gene expression(21). Therefore, it is reasonable to speculate that ingestion of paprika, which possesses abundant capsanthin, may modulate lipid metabolism.

The purpose of the present study was to evaluate the effect of capsanthin, the main carotenoid in paprika, on *in vivo* lipid metabolism in rats.

**Abbreviations:** ABC, ATP-binding cassette transporter; BD, basal diet; CAP, basal diet with purified capsanthin; EXT, basal diet with paprika extract; HIGH, high-capsanthin diet; LCAT, lecithin cholesterol acyltransferase; LOW, low-capsanthin diet; LPL, lipoprotein lipase; PAP, basal diet with paprika powder; RES, basal diet with residue of extract; SR-B1, scavenger receptor class B type 1.

* Corresponding author: Dr Koichi Aizawa, fax +81 287 39 1038, email Koichi_Aizawa@kagome.co.jp
Materials and methods

Animals

Known-pathogen-free male Crlj:WI rats (Wistar rats, aged 4 weeks) were purchased from Charles River Laboratories Japan, Inc. (Yokohama, Japan) and maintained on a normal CE-2 (CLEA, Tokyo, Japan) diet for 1 week before starting the experiment. All rats were housed individually in stainless-steel cages under controlled conditions (temperature 23 ± 1 ºC, humidity 55 ± 5 %, lights on from 07.00 to 19.00 hours). At the end of the experiments, the rats were anaesthetised with sodium pentobarbital and blood and liver samples were taken. Plasma samples were stored at −80 ºC until analysed. Livers were immediately frozen and kept at −80 ºC until analysed. All animals were treated in accordance with guidelines established by the Japanese Society of Nutrition and Food Science (Law 105 and Notification 6 of the Japanese government). The experimental protocol was approved by the Kagome Animal Use Committee.

Diet and preparation of samples

The basic diet contained the following ingredients (per kg): 250 g casein, 453 g maize starch, 200 g sucrose, 50 g maize oil, 35 g American Institute of Nutrition (AIN)-93 mineral mix, 10 g AIN-93 vitamin mixture and 2 g choline chloride. The diet ingredients were purchased from Oriental Yeast Co. (Tokyo, Japan). The composition of the other experimental diets resembled the basic diet, except that paprika powder, paprika extract, residue of paprika extract or purified capsanthin replaced an equivalent weight of maize starch.

Paprika powder was obtained by lyophilising paprika paste (TAT, Istanbul, Turkey). Paprika extract and its residue were prepared by organic solvent extraction. Briefly, paprika powder (20 g) was extracted by hexane–acetone–ethanol–toluene (10:7:6:7, by vol.) three times to separate the soluble organic components, including carotenoids. The extracts were combined and evaporated to produce the paprika extract (0.5 g). In addition, paprika extract residue (approximately 19.5 g) was acquired by the removal of organic solvents from the extraction residue. Capsanthin concentrations in the paprika powder, paprika extract residue and residue of paprika extract were determined by HPLC at 2.43, 64.97 and 19.5 g) was acquired by the removal of organic solvents (0.5 g). In addition, paprika extract residue (approximately 19.5 g) was acquired by the removal of organic solvents from the extraction residue. Capsanthin concentrations in the paprika powder, paprika extract residue and residue of paprika extract were determined by HPLC at 2.43, 64.97 and 0.62 mmol/kg, respectively.

Purified capsanthin for animal feed was extracted from commercially available non-acylated free capsanthin-containing powder (Capsanthal; BASF Japan Ltd, Tokyo, Japan), and purified by a chromatographic method. Briefly, Capsanthal was extracted by methanol and the extracts were applied to preparative HPLC (GL Science Inc., Tokyo, Japan) with a Soken pack octadecylsilyl (ODS-ST-C) column (Soken Chemical & Engineering Co., Ltd, Tokyo, Japan) and eluted with methanol. All fractions containing capsanthin were collected and evaporated. Crude capsanthin extracts were subjected to silica gel column chromatography (Wako-gel C-200; Wako, Tokyo, Japan) and sequential elutions of a solvent mixture of dichloromethane and methanol. The fractions containing capsanthin were pooled, and the solvent was removed in vacuo to obtain purified capsanthin. Capsanthin purity (>90 %) was determined by absorption spectroscopy and HPLC methodology.

Experimental design

In the present study, the main objective was to examine the effect of paprika or capsanthin ingestion on lipid metabolism. The feeding period of 2 weeks was determined by previous reports, which showed remarkable changes in lipid profiles and hepatic gene expression after ingestion of food ingredients. Furthermore, the maximum dose of capsanthin (0.49 mmol/kg diet) was chosen to produce an appreciable accumulation in the liver, according to previous experiments.

In experiment 1, after a maintenance period of 1 week, rats were divided into five groups of six animals each, with similar average body weights. The control group was fed a basal diet (BD), and the experimental groups were fed a basal diet with paprika powder (PAP), paprika extract (EXT), residue of paprika extract (RES) or purified capsanthin (CAP), as shown in Table 1. The diets and water were given ad libitum for 2 weeks. Faeces were collected and measured for 3 d at the end of the experiment.

In experiment 2, rats were divided into three groups of eight animals. The groups were fed either a basal diet (control) or a basal diet supplemented with one of two different capsanthin concentrations (low-capsanthin diet (LOW), 0.16 g purified capsanthin/kg diet; high-capsanthin diet (HIGH), 0.32 g purified capsanthin/kg diet). The diet capsanthin concentrations were 0.25 and 0.49 mmol/kg diet, respectively. The diets and water were provided ad libitum for 2 weeks. The concentration of liver capsanthin and relative mRNA concentrations of hepatic genes were measured in this experiment.

All blood samples were obtained from non-fasted rats. The concentrations of plasma total cholesterol, HDL-cholesterol and TAG were measured manually using commercial in vitro enzymic test kits (Wako, Tokyo, Japan).

The previously described method was modified and used for measuring carotenoids in liver. Briefly, the tissue was homogenised and saponified by the addition of 60 % KOH and 3 % butyraldehyde in ethanol, heated at 40 ºC for 30 min, and subsequently extracted (twice) with hexane–dichloromethane (4:1, v/v). The supernatant fraction was dried and reconstituted in a hexane–acetone–ethanol–toluene mixture.

Table 1. Composition of experimental diets in experiment 1 (g/kg diet)

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>BD</th>
<th>PAP</th>
<th>EXT</th>
<th>RES</th>
<th>CAP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Casein (g)</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
</tr>
<tr>
<td>Maize starch (g)</td>
<td>453</td>
<td>253</td>
<td>448</td>
<td>258</td>
<td>452</td>
</tr>
<tr>
<td>Sucrose (g)</td>
<td>200</td>
<td>200</td>
<td>200</td>
<td>200</td>
<td>200</td>
</tr>
<tr>
<td>Maize oil (g)</td>
<td>50</td>
<td>50</td>
<td>50</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>AIN-93 mineral mixture (g)</td>
<td>35</td>
<td>35</td>
<td>35</td>
<td>35</td>
<td>35</td>
</tr>
<tr>
<td>AIN-93 vitamin mixture (g)</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Choline chloride (g)</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Paprika powder (g)</td>
<td>–</td>
<td>200</td>
<td>–</td>
<td>200</td>
<td>–</td>
</tr>
<tr>
<td>Paprika extract (g)</td>
<td>–</td>
<td>–</td>
<td>5</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Residue of paprika extract (g)</td>
<td>–</td>
<td>–</td>
<td>195</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Purified capsanthin (g)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>0.32</td>
</tr>
</tbody>
</table>

BD, basal diet (capsanthin concentration 0-00 mmol/kg diet); PAP, basal diet with paprika powder (0.49 mmol/kg diet); EXT, basal diet with paprika extract (0-32 mmol/kg diet); RES, basal diet with residue of extract (0-12 mmol/kg diet); CAP, basal diet with purified capsanthin (0-49 mmol/kg diet); AIN, American Institute of Nutrition.
solvent. Analyses were performed using a Shimadzu SPD-M10 VP diode array detector (Shimadzu, Kyoto, Japan) and C30 carotenoid column (5 μm, 250 x 4.6 mm; YMC, Wilmington, NC, USA) with a flow rate of 1.0 ml/min.

Experimental diets were stored at −30°C until required, with fresh food provided daily. Food intake was measured daily, and body weight and water intake were measured three times per week.

**Real-time quantitative PCR analysis of gene expression**

Hepatic gene expression (relative mRNA concentrations) was measured in the rats from experiment 2. For analysis of gene expression, total RNA was extracted from rat liver samples using Trizol reagent (Invitrogen, Tokyo, Japan) according to the manufacturer’s instructions. RNA was spectrophotometrically quantified (A260) and its integrity verified by agarose gel electrophoresis using ethidium bromide for visualisation. Total RNA was reverse transcribed with a PrimeScript RT reagent kit (Takara Bio Inc., Shiga, Japan) for cDNA synthesis. The relative mRNA quantities of ATP-binding cassette transporter A1 (ABC-A1), apoA1, apoA5, apoC3, hepatic lipase, lecithin cholesterol acyltransferase (LCAT), lipoprotein lipase (LPL) and scavenger receptor class B type 1 (SR-B1) were measured by real-time quantitative PCR using SYBR Green I (Takara Bio Inc.) and the ABI PRISM 7000 Sequence Detection System (Applied Biosystems Japan Ltd, Tokyo, Japan). Real-time quantitative PCR was performed using a ninety-six-well PCR plate and a reaction mixture (50 μl) containing 25 μl SYBR Premix Ex Taq™ II (2 × ), 1 μl ROX Reference Dye (10 × ), 16 μl Rnase-free water (all from Takara Bio Inc.), 2 μl forward primer (10 μM), 2 μl reverse primer (10 μM) and 4 μl template. The primer oligonucleotides were selected using the online primer-select system (Takara Bio Inc.) and Primerpairs software (Applied Biosystems Japan Ltd) from database sequences. The primer sequences used for RT-PCR were as follows: 5'-CAG CAA CTA CAG TGG CGG TAA CCA-3' (forward) and 5'-AAT GCT TAG GGC ACA ATT CCT CCA CA-3' (reverse) for rat ABC-A1 (NM_178095); 5'-ATC GTT AGC ATT TCG TTT GAG-3' (reverse) for rat SR-B1 (NM_031541). The expression signal amplification curve using the Applied Biosystems software 7000 was performed using SYBR Green I (Takara Bio Inc.) and the ABI PRISM 7000 Sequence Detection System (Applied Biosystems Japan Ltd, Tokyo, Japan). Real-time quantitative PCR was performed using a ninety-six-well PCR plate and a reaction mixture (50 μl) containing 25 μl SYBR Premix Ex Taq™ II (2 × ), 1 μl ROX Reference Dye (10 × ), 16 μl Rnase-free water (all from Takara Bio Inc.), 2 μl forward primer (10 μM), 2 μl reverse primer (10 μM) and 4 μl template. The primer oligonucleotides were selected using the online primer-select system (Takara Bio Inc.) and Primerpairs software (Applied Biosystems Japan Ltd) from database sequences. The primer sequences used for RT-PCR were as follows: 5'-CAG CAA CTA CAG TGG CGG TAA CCA-3' (forward) and 5'-AAT GCT TAG GGC ACA ATT CCT CCA CA-3' (reverse) for rat ABC-A1 (NM_178095); 5'-ATC GTT AGC ATT TCG TTT GAG-3' (reverse) for rat SR-B1 (NM_031541). The expression signal amplification curve using the Applied Biosystems software 7000 was performed using SYBR Green I (Takara Bio Inc.) and the ABI PRISM 7000 Sequence Detection System (Applied Biosystems Japan Ltd, Tokyo, Japan). Real-time quantitative PCR was performed using a ninety-six-well PCR plate and a reaction mixture (50 μl) containing 25 μl SYBR Premix Ex Taq™ II (2 × ), 1 μl ROX Reference Dye (10 × ), 16 μl Rnase-free water (all from Takara Bio Inc.), 2 μl forward primer (10 μM), 2 μl reverse primer (10 μM) and 4 μl template. The primer oligonucleotides were selected using the online primer-select system (Takara Bio Inc.) and Primerpairs software (Applied Biosystems Japan Ltd) from database sequences. The primer sequences used for RT-PCR were as follows: 5'-CAG CAA CTA CAG TGG CGG TAA CCA-3' (forward) and 5'-AAT GCT TAG GGC ACA ATT CCT CCA CA-3' (reverse) for rat ABC-A1 (NM_178095); 5'-ATC GTT AGC ATT TCG TTT GAG-3' (reverse) for rat SR-B1 (NM_031541).

**Statistical analysis**

Results are expressed as mean values and standard deviations for six or eight rats. Data were analysed by one-way ANOVA. If significance was observed, post hoc pairwise comparisons were conducted using Tukey’s test. The correlations were investigated by Pearson’s coefficient test. All the analyses were performed with the SPSS 15.0J software computerised statistical analysis program (SPSS Japan Inc., Tokyo, Japan). P<0.05 was considered statistically significant.

**Results**

**Effects of paprika extracts on body weight and plasma lipids in rats (experiment 1)**

Diets containing different paprika fractions, paprika powder (PAP), paprika extract (EXT), residue of paprika extract (RES) and purified capsanthin (CAP), were examined in this experiment. There were no noticeable differences in body-weight gain, food intake and liver weight among the groups (Table 2). The wet faecal weights in the PAP and RES groups were significantly (P<0.05) higher than those in the basal diet (BD), EXT and CAP groups. There were no detectable differences in plasma total cholesterol and TAG concentrations. However, the HDL-cholesterol concentration in the CAP group was significantly (P<0.05) higher than that in the BD group. Significant differences in HDL-cholesterol concentration were not observed between the PAP, EXT and RES groups, and the BD and CAP groups. However, using Pearson’s correlation analysis, a statistically significant correlation (r 0.567; P<0.001) was found between the capsanthin concentration in the diet and the plasma HDL-cholesterol concentration.

**Effect of capsanthin on body weight, plasma lipid and hepatic mRNA levels (experiment 2)**

Two different concentrations of capsanthin were compared in this experiment. HDL-cholesterol levels tended to increase (17 % increase) when capsanthin was administered at a low dose (LOW group) and were significantly raised when administered at a high dose (HIGH group; P<0.01; 30 % increase). No significant differences were observed in body-weight gain, food intake, liver weight, and plasma total cholesterol and TAG concentrations among the groups (Table 3). There was no capsanthin content in the liver of animals fed the BD, but it was increased markedly with the administration of capsanthin-containing diets (P<0.001 between each group). Statistically significant relationships were observed between plasma HDL-cholesterol concentrations and capsanthin concentrations in the diet (r 0.597; P<0.005) or liver (r 0.583; P<0.005) (Fig. 1).
Real-time quantitative PCR analyses were performed to measure mRNA levels in rat liver from the three dietary groups (Fig. 2). Administration of capsanthin caused a significant increase ($P<0.05$) in the relative quantity of apoA5 mRNA levels in LOW and HIGH groups. Those levels were positively correlated with the capsanthin concentration in liver ($r=0.514$; $P<0.05$). Also, the relative quantity of LCAT mRNA in the HIGH group was significantly higher than that of the BD group. No significant differences or correlations were observed for relative quantities of other mRNA levels related to HDL-cholesterol metabolism in this experiment.

### Discussion

Previously, preliminary experiments revealed that administration of paprika increased plasma HDL-cholesterol in rats (K Aizawa and T Inakuma, unpublished results). The present study was conducted to examine what constituent of paprika ($C. annuum$) principally affected lipid metabolism in vivo in rats, hypothesising that capsanthin, the main carotenoid in paprika, might be responsible. As shown in Table 2, administration of purified capsanthin significantly increased ($P<0.05$; 44 % increase) plasma HDL-cholesterol levels. Furthermore, administration of two different capsanthin concentrations resulted in a dose-dependent increase in plasma HDL-cholesterol in experiment 2 (Table 3). Consequently, we concluded that the main active component was capsanthin. This conclusion was supported by the results from experiment 1, which showed that a significant correlation ($r=0.567$; $P<0.001$) was found between diet capsanthin concentrations and plasma HDL-cholesterol concentrations.

In experiment 1, it was observed that faecal weight in the PAP and RES groups was significantly higher ($P<0.05$; 202 and 213 % increase compared with the BD group, respectively) than that of the BD, EXT and CAP groups. These effects were attributed to the dietary fibre component of the experimental diets. It is reported that the administration of dietary fibre results in a dose-dependent increase in faecal weight ($P<0.05$). It was estimated that paprika powder (PAP) and residue of paprika extract (RES) are composed of 51.8 and 53.1 % carbohydrate (including dietary fibre), respectively. These factors raised the dietary fibre content by approximately 10 % in PAP and RES experimental diets. Additionally, it has been indicated that certain kinds of dietary fibre influence total cholesterol or TAG levels in blood, and increase bile acid or neutral sterol excretions ($P<0.05$). In the present study, we did not delve deeper into the effect of dietary fibre, because we were particularly intrigued by the ability

### Table 2. Body weight, food intake, liver weight, faecal weight and plasma lipid contents in rats fed basal and experiment 1 diets for 2 weeks (Mean values and standard deviations for six rats per group)

<table>
<thead>
<tr>
<th></th>
<th>BD</th>
<th>PAP</th>
<th>EXT</th>
<th>RES</th>
<th>CAP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight (g)*</td>
<td>241.90 ± 12.26</td>
<td>237.85 ± 18.91</td>
<td>238.84 ± 15.01</td>
<td>241.70 ± 9.69</td>
<td>235.78 ± 11.86</td>
</tr>
<tr>
<td>Body-weight gain (g)</td>
<td>107.48 ± 5.34</td>
<td>103.25 ± 13.65</td>
<td>104.66 ± 10.03</td>
<td>107.59 ± 8.32</td>
<td>101.77 ± 8.13</td>
</tr>
<tr>
<td>Food intake (g/d)</td>
<td>19.14 ± 0.68</td>
<td>18.39 ± 1.68</td>
<td>18.48 ± 0.90</td>
<td>19.74 ± 1.32</td>
<td>18.66 ± 1.04</td>
</tr>
<tr>
<td>Faecal weight (g per 3 d)†</td>
<td>1.36b ± 0.17</td>
<td>2.74a ± 0.43</td>
<td>1.56b ± 0.21</td>
<td>2.89a ± 0.84</td>
<td>1.37b ± 0.21</td>
</tr>
<tr>
<td>Liver weight (g)</td>
<td>7.74 ± 0.73</td>
<td>7.84 ± 1.00</td>
<td>7.72 ± 0.50</td>
<td>7.80 ± 0.56</td>
<td>7.70 ± 0.87</td>
</tr>
<tr>
<td>Plasma total cholesterol (mmol/l)</td>
<td>1.86 ± 0.55</td>
<td>2.42 ± 0.43</td>
<td>2.40 ± 0.19</td>
<td>2.13 ± 0.41</td>
<td>1.85 ± 0.25</td>
</tr>
<tr>
<td>Plasma HDL-cholesterol (mmol/l)</td>
<td>1.22c ± 0.24</td>
<td>1.61a,b ± 0.28</td>
<td>1.50a,b ± 0.12</td>
<td>1.37a,b ± 0.43</td>
<td>1.76a ± 0.25</td>
</tr>
<tr>
<td>Plasma TAG (mmol/l)</td>
<td>0.96 ± 0.43</td>
<td>1.02 ± 0.57</td>
<td>1.03 ± 0.16</td>
<td>0.76 ± 0.26</td>
<td>0.90 ± 0.48</td>
</tr>
</tbody>
</table>

BD, basal diet; PAP, basal diet with paprika powder; EXT, basal diet with paprika extract; RES, basal diet with residue of extract; CAP, basal diet with purified capsanthin.

*Mean values within a row with unlike superscript letters were significantly different ($P<0.05$).
†Body weight at the end of the 2-week feeding period.

### Table 3. Body weight, food intake, liver weight, plasma lipid contents and liver capsanthin concentration in rats fed basal and experiment 2 diets for 2 weeks (Mean values and standard deviations for eight rats per group)

<table>
<thead>
<tr>
<th></th>
<th>BD</th>
<th>LOW</th>
<th>HIGH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight (g)*</td>
<td>265.88 ± 13.82</td>
<td>261.95 ± 16.91</td>
<td>272.30 ± 18.18</td>
</tr>
<tr>
<td>Body-weight gain (g)</td>
<td>103.81 ± 7.98</td>
<td>101.03 ± 12.46</td>
<td>109.29 ± 11.45</td>
</tr>
<tr>
<td>Food intake (g/d)</td>
<td>23.74 ± 0.77</td>
<td>23.08 ± 1.55</td>
<td>23.82 ± 1.24</td>
</tr>
<tr>
<td>Liver weight (g)</td>
<td>7.32 ± 0.54</td>
<td>7.36 ± 1.07</td>
<td>8.14 ± 0.91</td>
</tr>
<tr>
<td>Plasma total cholesterol (mmol/l)</td>
<td>1.91 ± 0.37</td>
<td>1.91 ± 0.25</td>
<td>2.03 ± 0.50</td>
</tr>
<tr>
<td>Plasma HDL-cholesterol (mmol/l)</td>
<td>1.39b ± 0.22</td>
<td>1.63a,b ± 0.23</td>
<td>1.81a ± 0.29</td>
</tr>
<tr>
<td>Plasma TAG (mmol/l)</td>
<td>0.81 ± 0.12</td>
<td>0.95 ± 0.37</td>
<td>1.02 ± 0.21</td>
</tr>
<tr>
<td>Liver capsanthin (mmol/mg wet tissue)</td>
<td>0.00a ± 0.00</td>
<td>0.22a ± 0.05</td>
<td>0.40b ± 0.14</td>
</tr>
</tbody>
</table>

BD, basal diet; LOW, basal diet with purified capsanthin (0.16 g/kg diet); HIGH, basal diet with purified capsanthin (0.32 g/kg diet).

*Mean values within a row with unlike superscript letters were significantly different ($P<0.05$).
†Body weight at the end of the 2-week feeding period.
of capsanthin to increase HDL-cholesterol levels. The cholesterol-lowering effects of dietary fibre are primarily observed in the LDL portion, and dietary fibre did not produce substantial changes in HDL-cholesterol levels(33). We may be able to observe blood lipid changes induced by the addition of paprika-derived dietary fibre in the experimental diet if the experimental duration is extended.

Quantitative analysis of liver mRNA in the capsanthin-administered group showed a significant increase in apoA5 and LCAT expression, without notable changes in ABC-A1, apoA1, apoC3, hepatic lipase, LPL, and SR-B1 (Fig. 2). HDL is synthesised through a complex pathway(34). HDL assembly initially involves cell surface ABC-A1 transporter-mediated transfer of phospholipids and cholesterol to extracellular lipid-poor apoA1. This is followed by remodelling of the plasma compartment of HDL particles, by the esterification of cholesterol by the enzyme LCAT, the exchange between HDL and other lipoproteins of both apolipoproteins (apoA1 and other less abundant apolipoproteins) and lipids, and the putative transfer of additional cellular cholesterol to the growing particles by SR-B1(35). Finally, HDL lipid hydrolysis is mediated by various lipases (LPL, hepatic lipase and endothelial lipase) and exchange of lipids by the cholesteryl ester transfer protein and by the phospholipid transfer protein. The increase in LCAT and apoA1 gene expression would normally contribute to an increase in HDL-cholesterol concentrations. In the present study, the hepatic apoA1 mRNA level among all groups was not significantly different, but LCAT mRNA was significantly increased by capsanthin administration. Therefore, one reason for the higher concentration of HDL-cholesterol in rats fed capsanthin diets could be due to alterations in the expression and/or activity of LCAT.

The role that LCAT plays in HDL metabolism has been established in both patients and animals with LCAT deficiency, as well as in animals over-expressing human LCAT. LCAT deficiency is associated with severely reduced concentrations of HDL, whereas transgenic animals over-expressing LCAT show markedly higher plasma HDL levels(36–38). However, a number of studies point to a relationship between LCAT and apoA1 expression(39,40).

The reason for the discrepancy in the present study that hepatic apoA1 mRNA levels were not correlated with LCAT mRNA levels is unclear. On the other hand, although the plasma apoA1 concentration was drastically reduced in LCAT knockout mice, there was no reduction in hepatic apoA1 mRNA(41), suggesting that both genes may not be regulated in a coordinated manner. At present, the molecular mechanisms regulating LCAT are not well understood. However, capsanthin may only regulate LCAT mRNA expression, without affecting apoA1 mRNA expression.

Additionally, a significant increase in hepatic apoA5 mRNA levels was observed by administration of capsanthin (Fig. 2). ApoA5 is a newly discovered apolipoprotein, which was identified independently by two groups(42,43). Disruption of the apoA5 gene in mice resulted in hypertriacylglycerolaemia, whereas overexpression led to decreased plasma TAG concentrations, thus establishing an important role for this protein in TAG homeostasis(44,45). Marc`ais et al.(46) reported that a mutation in the apoA5 gene led to severe hypertriacylglycerolaemia by exerting a dominant-negative effect on the plasma lipolytic system for TAG-rich lipoproteins. They suggested that apoA5 accelerated lipolysis by facilitating the interaction of TAG-rich lipoproteins with hepamin sulfate-proteoglycan-bound LPL. In the present study, plasma TAG levels did not change appreciably, in spite of the increase in the apoA5 mRNA level. One possibility is that the LPL mRNA level did not change (Fig. 2), indicating that LPL activity was not enhanced by administration of capsanthin. Also, only a small amount of capsanthin was supplemented into the normal diet for a short period of time (2 weeks). Alteration of the quantity and duration of capsanthin administration may clarify these remarkable observations.

Qu et al.(47) indicated that apoA5 exerted an effect on HDL-cholesterol metabolism in APOC3 transgenic mice. They reported that increased apoA5 production promoted α-HDL formation, resulting in significant increases in both the number and size of HDL particles. In addition, increased apoA5 levels were associated with enhanced LCAT activity. It appears that HDL particles with increased apoA5 content were associated with increased cholesterol-loading capacity. This hypothesis is consistent with the present results. Capsanthin may be thought to act in a similar manner.
Capsanthin improves lipid metabolism

K. A. designed all experiments, carried out the main experimental work and wrote the manuscript. T. I. supported the idea of the manuscript and, as the director of the Biogenics Research Department, provided a number of suggestions. The authors also wish to thank the staff of the Biogenics Research Department, Kagome Co., Ltd, for their help with sample and experiment preparation.

None of the authors had any personal or financial conflict of interest.

References


